Agenus Inc. (NASDAQ: AGEN) will release its first quarter 2014 financial
results before the market opens on May 8, 2014.
Agenus executives will host a conference call at 11:00 a.m. Eastern Time
that same day. To access the live call, dial 647-426-1845. The call will
also be webcast and will be accessible from the company’s website at www.agenusbio.com/webcast/.
A replay will be available approximately two hours after the call
through midnight Eastern Time on July 8, 2014. The replay number is
416-915-1035, and the access code is 571716. The replay will also be
available on the company’s website approximately two hours after the
live call.
About Agenus
Agenus is an immuno-oncology company developing
a portfolio of checkpoint modulators (CPMs), heat shock protein vaccines
and adjuvants. Agenus’ checkpoint modulator programs target GITR, OX40,
CTLA-4, LAG-3, TIM-3 and PD-1. The company’s proprietary discovery
engine Retrocyte Display® is used to generate fully human
therapeutic antibody drug candidates. The Retrocyte Display platform
uses a high-throughput approach incorporating IgG format human antibody
libraries expressed in mammalian B-lineage cells. Agenus’ heat shock
protein vaccines for cancer and infectious disease are in Phase 2
studies. The company’s QS-21 Stimulon® adjuvant platform is
extensively partnered with GlaxoSmithKline and Janssen and includes
several candidates in Phase 3 trials. Among Agenus and its partners, 22
programs are in clinical development. For more information, please visit www.agenusbio.com,
or connect with the company on Facebook,
LinkedIn,
Twitter
and Google+.
Retrocyte Display and QS-21 Stimulon are registered trademarks of Agenus
and its subsidiaries.
Copyright Business Wire 2014